Summary
Biological therapy using a combination of lymphokine and tumor infiltrating lymphocytes (TILs) is a new approach to the treatment of patients with advanced cancer. To improve the potency of TILs, new cytokines with T-cell stimulatory effects used alone or in combination with interleukin-2 (IL-2) are currently being investigated. We have studied the effect of interleukin-7 (IL-7) on TILs derived from renal cell carcinoma. Our data demonstrated that five of ten TILs proliferated in response to IL-7 alone. This proliferative response was 73–90% less than that obtained with IL-2 alone. The use of IL-7 plus IL-2 resulted in a 1.2- to 4.7-fold increase in proliferation of six of ten TILs compared with IL-2 alone. IL-7-driven TIL growth was consistently blocked by anti-IL-2, anti-IL-2R and anti-IL-7 antibodies (37.2%, 41.6% and 82.2% suppression, respectively). The expression of IL-2 receptors was also significantly increased in the presence of IL-7 or IL-7 phytohemagglutinin (40.6+3.8 and 72.5+1.5). In comparison with IL-2, IL-7 treatment was associated with a decrease in CD56 (46.3%±19 vs 10%±4.9) and increase in CD3 (29.3%±12 vs 73%±6.4) and CD 4 (19.3%±15 vs 58%±10). These studies suggest that in some renal TILs, IL-7 and IL-2 can have a synergistic proliferative effect. The IL-7 stimulatory effect appears to be mediated via both an IL-2 pathway and an IL-7-independent pathway.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alderson MR, Sassenfeld HM, Widmer MB (1990) Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine activated killer cells from human peripheral blood. J Exp Med 172:577
Armitage RJ, Namen AE, Sasenfeld HM, Grabstein KH (1990) Regulation of human T cell proliferation by Interleukin-7. J Immunol 144:938
Belldegrun A, Webb DA, Austin HA III, Steinberg SM, White DE, Linehan WM, Rosenberg SA (1987) Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 106:817
Beldegrun A, Muul LM, Rosenberg SA (1988) Interleukin-2 expanded tumor infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res 48:206
Bertagnolli M, Herrmann S (1990) Il-7 supports the generation of cytotoxic T lymphocytes from thymocytes. Multiple lymphokynes required for proliferation and toxicity. J Immunol 145:1706
Chazen GD, Pereira GMB, LeGros G, Gillis, S, Shevach E. Interleukin 7 is a T-cell growth factor. Proc Natl Acad Sci USA 86:5923
Conlon PJ, Morrisey PJ, Nordan RP, Grabstein KH, Prickett KS, Reed SG, Goodwin R, Cosman D, Namen AE (1989) Murine thymocytes proliferate in direct response to interleukin-7. Blood 74:1368
Gomella LG, Sargent ER, Wade TP, Anglard P, Linehan WM, Kasid A (1989) Expression of transforming growth fctor alpha in normal human adult kidney and enhanced expression of transformed growth factors alpha and beta 1 in renal cell carcinoma. Cancer Res 49:6972
Grabstein KH, Namen AE, Shanebeck K, Voice RF, Reed SG, Widmer MB (1990) Regulation of T cell proliferation by IL-7. J Immunol 144:3015
Henney CS (1989) Interleukin-7: effects on early events in lumphopoiesis. Immunol Today 10:170
Lee G, Namen AE, Gillis S, Ellingsworth LR, Kincade PW, (1989) Normal B cell precursors responsive to recombinant murine IL-7 and inhibition of IL-7 activity by transforming growth factor beta. J Immunol 142:3875
Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA, Rosenberg SA (1986) Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58:2764
Lynch DH, Miller RE (1990) Induction of murine lymphokine activated killer cells by recombinant IL-7. J Immunol 145:1983
Morrisey PJ, Goodwin R, Nordan RP, Anderson D, Grabstein KH, Cosman D, Sims J, Lupton S, Acres B, Reed SG, Mochizucki DY, Eisenman J, Conlon PJ, Namen AE (1989) Recombinant interleukin 7, pre B cell growth factor, has costimulatory activity on purified mature T cells. J Exp Med 169:707
Namen AE, Schmierer AE, March CJ, Overell RW, Park LS, Urdal DL, Mochizucki DY (1988) B cell precursor growthpromoting activity. Purification and characterization of a growth factor active on lymphocyte precursors. J Exp Med 167:1988
Rosenberg SA, Schwartz SL, Spiess PJ (1988) Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon and tumor infiltrating lymphocytes. J Natl Cancer Inst 80:1393
Sporn MB, Roberts AB, Wakefield LM, Assoian RK (1986) Transforming growth factor-B: biological function and chemical structure. Science 233:532
Topalian SL, Muul LM, Solomon D, Rosenberg SA (1987) Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 102:127
Valentine MA, Tsoukas CD, Rhodes G, Vaughan JH, Carson DA (1985) Phytohemoagglutinin binds to the 20kDa-molecules of the T3 complex. Eur J Immunol 15:851
Watson JD, Morrisey PJ, Namen AE, Conlon PJ, Widmer MB (1989) Effects of IL-7 on the growth of fetal thymocytes in culture J Immunol 143:1215
Welch PA, Namen AE, Goodwin RG, Armitage R, Cooper MD (1989) Human IL-7: a novel T cell growth factor. J Immunol 143:3562
Author information
Authors and Affiliations
Additional information
This paper was selected for publication in Urological Research from the program of the 1991 meeting of the European Society of Urological Oncology and Endocrinology (ESUOE)
Rights and permissions
About this article
Cite this article
Ditonno, P., Tso, C.L., Sakata, T. et al. Regulatory effects of interleukin-7 on renal tumor infiltrating lymphocytes. Urol. Res. 20, 205–210 (1992). https://doi.org/10.1007/BF00299718
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00299718